Male Breast Cancer (cont.)
Melissa Conrad Stöppler, MD
Melissa Conrad Stöppler, MD, is a U.S. board-certified Anatomic Pathologist with subspecialty training in the fields of Experimental and Molecular Pathology. Dr. Stöppler's educational background includes a BA with Highest Distinction from the University of Virginia and an MD from the University of North Carolina. She completed residency training in Anatomic Pathology at Georgetown University followed by subspecialty fellowship training in molecular diagnostics and experimental pathology.
Dennis Lee, MD
Dr. Lee was born in Shanghai, China, and received his college and medical training in the United States. He is fluent in English and three Chinese dialects. He graduated with chemistry departmental honors from Harvey Mudd College. He was appointed president of AOA society at UCLA School of Medicine. He underwent internal medicine residency and gastroenterology fellowship training at Cedars Sinai Medical Center.
William C. Shiel Jr., MD, FACP, FACR
Dr. Shiel received a Bachelor of Science degree with honors from the University of Notre Dame. There he was involved in research in radiation biology and received the Huisking Scholarship. After graduating from St. Louis University School of Medicine, he completed his Internal Medicine residency and Rheumatology fellowship at the University of California, Irvine. He is board-certified in Internal Medicine and Rheumatology.
In this Article
- Male breast cancer facts
- What is male breast cancer?
- How common is male breast cancer?
- What are causes and risk factors of male breast cancer?
- What are the different types of male breast cancer?
- What are male breast cancer symptoms and signs?
- How is male breast cancer diagnosed?
- What is staging of male breast cancer?
- What is the treatment for male breast cancer?
- What is the outcome (prognosis) of male breast cancer?
- Find a local Oncologist in your town
What is the outcome (prognosis) of male breast cancer?
The prognosis of a patient with male breast cancer is considered similarly to breast cancer in a woman. As in women, the size and extent (stage) of tumor are the most important factors in the prognosis for male breast cancer. Overall survival rates for each tumor stage are similar for men and women. Since men have less breast tissue than women, it is more common for breast cancers in men to have spread beyond the breast when they are identified, resulting in a more advanced tumor stage at diagnosis.
Disease-specific five-year survival rates (meaning the percentage of patients who do not die of the disease for at least five years following diagnosis) reported for male breast cancer by stage are as follows:
- Stage 0 - 100%
- Stage I - 100%
- Stage II - 91%
- Stage III - 72%
- Stage IV - 20%
These survival rates were calculated using historical data, and it is likely that current treatments will lead to even greater survival rates for those recently diagnosed.
The American Cancer Society
United States. "Breast Cancer." National Cancer Institute, U.S. National Institutes of Health. <http://www.cancer.gov/cancertopics/types/breast>.
United States. "Surveillance Epidemiology and End Results." National Cancer Institute, U.S. National Institutes of Health. <http://www.seer.cancer.gov>.
Find support and advances in treatment.